吸入式一氧化氮市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品類型、應用、地區和競爭細分，2020-2030 年

2024 年全球吸入式一氧化氮市場價值為 7.3212 億美元，預計在預測期內將實現強勁成長，到 2030 年的複合年成長率為 7.12%。全球吸入式一氧化氮 (iNO) 市場已成為醫療保健和製藥行業的關鍵部門，在各種呼吸和心血管疾病的管理中發揮關鍵作用。吸入一氧化氮是一種無色、幾乎無味的氣體，因其血管擴張和抗炎特性而得到廣泛認可，使其成為重要的治療選擇。由於慢性阻塞性肺病 (COPD)、氣喘和急性呼吸窘迫症候群 (ARDS) 等呼吸道疾病的盛行率不斷上升，市場正在經歷顯著成長。吸入式一氧化氮在新生兒學中的應用不斷擴大，用於治療新生兒持續性肺動脈高壓，這對市場擴張做出了巨大貢獻。例如，在美國，食品藥物管理局（FDA）對吸入一氧化氮系統的批准和使用實施嚴格的指導方針，其中包括廣泛的臨床試驗和上市後監測。 《綜合環境反應、賠償和責任法案》（CERCLA）將一氧化氮歸類為危險物質，需要精心處理和處置。這些法規也適用於國際，為在全球營運的市場參與者帶來了額外的挑戰。

該市場的特點是研發活動激增，旨在探索新的應用並提高吸入一氧化氮療法的療效。製藥公司正在積極參與臨床試驗，以評估吸入一氧化氮在治療常規用途以外的疾病方面的可行性，例如治療與 COVID-19 相關的呼吸道併發症。應用的多樣化正在促進創新並推動市場成長。

主要市場促進因素

呼吸系統疾病盛行率上升

主要市場挑戰

吸入式一氧化氮治療成本高昂

主要市場趨勢

遠距醫療和遠距病人監控的興起

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第4章：全球吸入式一氧化氮市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品類型（氣體、輸送系統）
  • 依應用（新生兒呼吸治療、氣喘及慢性阻塞性肺病、急性呼吸窘迫症候群、瘧疾治療、結核病治療、其他應用）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 依產品類型
  • 按應用
  • 按地區

第5章：亞太吸入式一氧化氮市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品類型
  • 按應用
  • 按國家
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第6章：歐洲吸入式一氧化氮市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第7章：北美吸入式一氧化氮市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第8章：南美洲吸入式一氧化氮市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第9章：中東與非洲吸入式一氧化氮市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 埃及

第 10 章：市場動態

• 驅動程式
• 挑戰

第 11 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 12 章：全球吸入式一氧化氮市場：SWOT 分析

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Linde PLC
• Air Liquide Healthcare
• BOC Healthcare
• Matheson Tri-Gas Inc.
• Merck KGaA
• Mallinckrodt Pharmaceuticals (Novoteris)
• Nu-Med Plus Inc.
• Perma Pure LLC
• Praxair Distribution Inc.
• HALMA PLC

第 15 章：策略建議

第16章調查會社について,免責事項

Global Inhaled Nitric Oxide Market was valued at USD 732.12 million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 7.12% through 2030. The Global Inhaled Nitric Oxide (iNO) Market has emerged as a critical sector within the healthcare and pharmaceutical industry, playing a pivotal role in the management of various respiratory and cardiovascular disorders. Inhaled Nitric Oxide, a colorless and virtually odorless gas, has gained widespread recognition for its vasodilatory and anti-inflammatory properties, making it an essential therapeutic option. The market is witnessing significant growth due to the increasing prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and acute respiratory distress syndrome (ARDS). The expanding applications of inhaled nitric oxide in neonatology, where it is employed to treat persistent pulmonary hypertension in newborns, contribute substantially to market expansion. For instance, in the U.S., the Food and Drug Administration (FDA) enforces strict guidelines for the approval and use of inhaled nitric oxide systems, which include extensive clinical trials and post-market surveillance. The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) classifies nitric oxide as hazardous, requiring meticulous handling and disposal. These regulations are also applicable internationally, creating additional challenges for market participants operating globally.

The market is characterized by a surge in research and development activities, aiming to explore novel applications and enhance the efficacy of inhaled nitric oxide therapies. Pharmaceutical companies are actively engaged in clinical trials to assess the feasibility of inhaled nitric oxide in addressing conditions beyond its conventional use, such as in the treatment of COVID-19-related respiratory complications. This diversification of applications is fostering innovation and driving market growth.

Key Market Drivers

Rising Prevalence of Respiratory Disorders

The rising prevalence of respiratory disorders stands as a primary catalyst propelling the global inhaled nitric oxide (iNO) market to unprecedented heights. Over the past few years, there has been a noticeable surge in the incidence of respiratory conditions worldwide, creating an urgent demand for innovative and effective treatment modalities. Conditions such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and pulmonary hypertension have become more prevalent, necessitating advanced therapeutic interventions. For instance, the Centers for Disease Control and Prevention reported that in 2022, approximately 1 in every 10 infants born in the U.S. was preterm. Preterm birth, defined as delivering a baby before 37 weeks of pregnancy, presents substantial health risks to infants, including respiratory distress syndrome and persistent pulmonary hypertension.

Inhaled nitric oxide has emerged as a crucial player in the healthcare sector, offering a promising solution for managing and improving outcomes in patients with respiratory disorders. Its vasodilatory effects and ability to enhance oxygenation make it particularly valuable in the treatment of conditions where respiratory function is compromised. The global healthcare landscape is witnessing a paradigm shift with an increasing focus on addressing respiratory health issues, and inhaled nitric oxide has positioned itself at the forefront of this transformative wave. For instance, according to April 2021 statistics from the Asthma and Allergy Foundation of America, approximately 20 million adults aged 18 and older in the United States suffer from asthma. This high prevalence of respiratory disorders in the country creates a steady demand for inhaled nitric oxide, contributing to the growth of the market in the United States.

Key Market Challenges

High Cost of Inhaled Nitric Oxide Treatment

The intricate processes involved in the production, storage, and delivery of inhaled nitric oxide contribute to the elevated overall treatment expenses. The cost-intensive nature of these procedures poses a challenge to the affordability of inhaled nitric oxide treatment, particularly in regions where healthcare budgets are constrained. Striking a delicate balance between ensuring profitability for manufacturers and affordability for healthcare systems is imperative for the sustained growth of the market.

The high cost of inhaled nitric oxide treatment exacerbates global disparities in healthcare access. Regions with limited financial resources may find it challenging to integrate this therapeutic option into their healthcare systems, potentially leaving patients without access to a treatment that could significantly improve their respiratory conditions. Bridging this accessibility gap requires concerted efforts to develop pricing models that accommodate diverse economic landscapes.

Key Market Trends

Rise Of Telehealth and Remote Patient Monitoring

The rise of telehealth and remote patient monitoring is playing a pivotal role in boosting the Global Inhaled Nitric Oxide (iNO) Market. As healthcare continues to evolve, telehealth platforms and remote monitoring technologies have become integral components in the management of respiratory disorders, contributing significantly to the growth of inhaled nitric oxide therapies. Telehealth facilitates virtual consultations, allowing healthcare providers to remotely assess patients' respiratory conditions, discuss symptoms, and make informed decisions about treatment plans. In the context of inhaled nitric oxide, this trend enables healthcare professionals to monitor patients' responses to treatment in real-time, adjusting dosages or interventions as necessary. This remote monitoring capability not only enhances the efficiency of healthcare delivery but also ensures that patients receive timely and personalized care, particularly in the management of chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD) or asthma.

Key Market Players

• Linde PLC
• Air Liquide Healthcare
• BOC Healthcare
• Matheson Tri-Gas Inc.
• Merck KGaA
• Mallinckrodt Pharmaceuticals (Novoteris)
• Nu-Med Plus Inc.
• Perma Pure LLC
• Praxair Distribution Inc.
• HALMA PLC

Report Scope:

In this report, the Global Inhaled Nitric Oxide Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Inhaled Nitric Oxide Market, By Product Type:

• Gas
• Delivery Systems

Inhaled Nitric Oxide Market, By Application:

• Neonatal Respiratory Treatment
• Asthma and COPD
• Acute Respiratory Distress Syndrome
• Malaria Treatment
• Tuberculosis Treatment
• Other Applications

Inhaled Nitric Oxide Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Inhaled Nitric Oxide Market.

Available Customizations:

Global Inhaled Nitric Oxide Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Inhaled Nitric Oxide Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Product Type (Gas, Delivery Systems)
  • 4.2.2. By Application (Neonatal Respiratory Treatment, Asthma and COPD, Acute Respiratory Distress Syndrome, Malaria Treatment, Tuberculosis Treatment, Other Applications)
  • 4.2.3. By Region
  • 4.2.4. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Product Type
  • 4.3.2. By Application
  • 4.3.3. By Region

5. Asia Pacific Inhaled Nitric Oxide Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type
  • 5.2.2. By Application
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Inhaled Nitric Oxide Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Product Type
      • 5.3.1.2.2. By Application
  • 5.3.2. India Inhaled Nitric Oxide Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Product Type
      • 5.3.2.2.2. By Application
  • 5.3.3. Australia Inhaled Nitric Oxide Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Product Type
      • 5.3.3.2.2. By Application
  • 5.3.4. Japan Inhaled Nitric Oxide Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Product Type
      • 5.3.4.2.2. By Application
  • 5.3.5. South Korea Inhaled Nitric Oxide Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Product Type
      • 5.3.5.2.2. By Application

6. Europe Inhaled Nitric Oxide Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Inhaled Nitric Oxide Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Germany Inhaled Nitric Oxide Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Spain Inhaled Nitric Oxide Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
  • 6.3.4. Italy Inhaled Nitric Oxide Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By Application
  • 6.3.5. United Kingdom Inhaled Nitric Oxide Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By Application

7. North America Inhaled Nitric Oxide Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Inhaled Nitric Oxide Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
  • 7.3.2. Mexico Inhaled Nitric Oxide Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Canada Inhaled Nitric Oxide Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application

8. South America Inhaled Nitric Oxide Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Inhaled Nitric Oxide Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Argentina Inhaled Nitric Oxide Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Colombia Inhaled Nitric Oxide Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application

9. Middle East and Africa Inhaled Nitric Oxide Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Inhaled Nitric Oxide Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Saudi Arabia Inhaled Nitric Oxide Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
  • 9.3.3. UAE Inhaled Nitric Oxide Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application
  • 9.3.4. Egypt Inhaled Nitric Oxide Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Product Type
      • 9.3.4.2.2. By Application

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Inhaled Nitric Oxide Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Linde PLC
  • 14.1.1. Company Snapshot
  • 14.1.2. Products & Services
  • 14.1.3. Current Capacity Analysis
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Air Liquide Healthcare
• 14.3. BOC Healthcare
• 14.4. Matheson Tri-Gas Inc.
• 14.5. Merck KGaA
• 14.6. Mallinckrodt Pharmaceuticals (Novoteris)
• 14.7. Nu-Med Plus Inc.
• 14.8. Perma Pure LLC
• 14.9. Praxair Distribution Inc.
• 14.10.HALMA PLC

15. Strategic Recommendations

16. About Us & Disclaimer